A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.

被引：0

作者：

Johnson, Melissa ^{[1
]}

Ulahannan, Susanna ^{[2
]}

Vandross, Andrae ^{[3
]}

Park, Haeseong ^{[4
]}

Faoro, Leo ^{[5
]}

Faggioni, Raffaella ^{[5
]}

Li, Jing ^{[5
]}

Chang, Yu-Lin ^{[5
]}

Uttamsingh, Shailaja ^{[5
]}

Tolcher, Anthony ^{[6
]}

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[2] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA

[3] NEXT Oncol, Austin, TX USA

[4] Washington Univ, St Louis, MO 63110 USA

[5] Exelixis Inc, Alameda, CA USA

[6] NEXT Oncol, San Antonio, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT254

引用

页数：1